

# Joyce O Shaughnessy

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/844192/joyce-oshaughnessy-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140  
papers

6,500  
citations

31  
h-index

80  
g-index

161  
ext. papers

8,226  
ext. citations

6.5  
avg, IF

5.29  
L-index

#	Paper	IF	Citations
140	Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review.. <i>Pharmacoeconomics</i> , <b>2022</b> , 1	4.4	0
139	AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer.. <i>Therapeutic Advances in Medical Oncology</i> , <b>2022</b> , 14, 17588359221083956	5.4	4
138	Abstract OT2-11-08: AMEERA-5 : A randomized, double-blind phase 3 study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer. <i>Cancer Research</i> , <b>2022</b> , 82, OT2-11-08-OT2-11-08	10.1	
137	Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib. <i>Cancer Research</i> , <b>2022</b> , 82, PD2-03-PD2-03	10.1	
136	Abstract PD8-04: Safety and anti-tumor activity of ARX788 in HER2-positive metastatic breast cancer patients whose disease is resistant/refractory to HER2 targeted agents (trastuzumab, ADCs, TKIs, and bispecific antibodies): ACE-Breast-01 trial results. <i>Cancer Research</i> , <b>2022</b> , 82, PD8-04-PD8-04	10.1	0
135	Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). <i>Cancer Research</i> , <b>2022</b> , 82, P5-16-15-P5-16-15	10.1	
134	Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial. <i>Cancer Research</i> , <b>2022</b> , 82, PD10-05-PD10-05	10.1	0
133	Abstract P2-10-08: Assessment of risk factors for HER2+ breast cancer recurrence: A literature review. <i>Cancer Research</i> , <b>2022</b> , 82, P2-10-08-P2-10-08	10.1	
132	Abstract OT2-07-01: The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early-stage breast cancer. <i>Cancer Research</i> , <b>2022</b> , 82, OT2-07-01-OT2-07-01	10.1	
131	Abstract OT2-11-01: EMBER-3: A randomized phase 3 study of LY3484356, a novel, oral selective estrogen receptor degrader vs investigator choice of endocrine therapy of either fulvestrant or exemestane, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. <i>Cancer Research</i> , <b>2022</b> , 82, OT2-11-01-OT2-11-01	10.1	0
130	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. <i>Cancer Research</i> , <b>2022</b> , 82, GS1-01-GS1-01	10.1	1
129	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.. <i>New England Journal of Medicine</i> , <b>2022</b> , 386, 942-950	59.2	18
128	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.. <i>Breast Cancer Research and Treatment</i> , <b>2022</b> , 1	4.4	1
127	339 Immune profiling to investigate improved survival in patients with metastatic triple-negative breast cancer receiving trilaciclib prior to chemotherapy <b>2021</b> , 9, A365-A365		
126	Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 1	4.4	6
125	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 1-8	7.3	4
124	Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer. <i>Cancer Management and Research</i> , <b>2021</b> , 13, 8179-8189	3.6	

123	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1529-1541	59.2	108
122	Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. <i>JAMA Network Open</i> , <b>2021</b> , 4, e214103	10.4	3
121	Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1080-1080	2.2	0
120	Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpressing solid tumors: Results from two phase 1 clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1038-1038	2.2	6
119	Assessment of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1077-1077	2.2	1
118	Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS1107-TPS1107	2.2	1
117	Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1020-1020	2.2	5
116	Reply to K. Hashimoto and A. Shimomura. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1507-1508	2.2	
115	AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS1104-TPS1104	2.2	0
114	Molecular profiles of genomically high risk ER+ HER2- breast cancer tumors classified as functionally basal or luminal B by the 80-gene signature.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 563-563	2.2	1
113	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 80	7.8	2
112	Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 188, 179-190	4.4	2
111	Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A <b>2021</b> ,		10
110	Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2021</b> , 21, e575-e583	3	4
109	Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. <i>European Journal of Cancer</i> , <b>2021</b> , 152, 223-232	7.5	4
108	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1105-1113	12.9	10
107	Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1014-1014	2.2	12
106	Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1087-1087	2.2	2

105	High-risk breast cancer genes at 8q22-24 and their role in over 5,000 patients evaluated with the 70-gene risk of recurrence assay.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3569-3569	2.2	
104	SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS1104-TPS1104	2.2	1
103	Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 182, 243-244	4.4	
102	EARLY real-world treatment and dosing patterns of ribociclib for metastatic breast cancer (mBC): A retrospective observational study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e13059-e13059	2.2	0
101	Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e12648-e12648	2.2	1
100	Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrightNess Randomized Clinical Trial. <i>JAMA Surgery</i> , <b>2020</b> , 155, e195410	5.4	31
99	Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. <i>Scientific Reports</i> , <b>2020</b> , 10, 11203	4.9	3
98	Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 184, 161-172	4.4	1
97	Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. <i>Breast Cancer Research</i> , <b>2020</b> , 22, 114	8.3	6
96	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3987-3998	2.2	152
95	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. <i>Cancer Research</i> , <b>2020</b> , 80, 5427-5434	10.1	32
94	Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 184, 53-62	4.4	32
93	De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. <i>Oncologist</i> , <b>2020</b> , 25, e214-e222	5.7	15
92	Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 70-83	1	5
91	Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 1587-1601	21.7	49
90	Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 1641-1653	3.6	5
89	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. <i>Nature Communications</i> , <b>2019</b> , 10, 1373	17.4	137
88	A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1057-1057	2.2	16

87	Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 510-510	2.2	4
86	CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1078-1078	2.2	2
85	First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1078-1078	2.2	1
84	Imaging features of genomic instability in circulating tumor cells (CTCs) from metastatic triple-negative breast cancer (metTNBC) patients (pts) who received PIKTOR.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e14527-e14527	2.2	
83	Treatment patterns and barriers involving the use of CDK4/6 inhibitors for women with HR+, HER2- breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 27-27	2.2	
82	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 741-751	59.2	308
81	Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2433-2441	12.9	33
80	Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 497-509	21.7	341
79	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 170, 547-557	4.4	21
78	Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 170, 535-545	4.4	49
77	Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3348-3357	12.9	15
76	Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 69, 204-214	14.4	34
75	IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer. <i>Cancer Research</i> , <b>2018</b> , 78, 5243-5258	10.1	78
74	IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS1117-TPS1117	2.2	9
73	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 168, 127-134	4.4	62
72	Overall survival in MERIDIAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , <b>2018</b> , 90, 153-155	7.5	13
71	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. <i>Npj Breast Cancer</i> , <b>2018</b> , 4, 41	7.8	30
70	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR/HER2 Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5218-5224	12.9	327

69	Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 165, 329-341	4.4	31
68	Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. <i>European Journal of Cancer</i> , <b>2017</b> , 76, 205-215	7.5	11
67	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2141-2148	2.2	177
66	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. <i>European Journal of Cancer</i> , <b>2017</b> , 70, 146-155	7.5	88
65	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1008-1008	2.2	82
64	Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1008-1008	2.2	12
63	Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1038-1038	2.2	27
62	Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1089-1089	2.2	9
61	Androgen receptor (AR) activation in breast cancer (BC) liver metastases.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11619-11619	2.2	3
60	Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 520-520	2.2	18
59	A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. <i>Oncotarget</i> , <b>2017</b> , 8, 85120-85135	3.3	11
58	Experience and impact of alopecia in patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 239-239	2.2	
57	Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1016-1016	2.2	1
56	Phosphoproteomic analysis of matched primary breast cancer (BC) and lymph node (LN) metastases.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11620-11620	2.2	
55	Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 514-514	2.2	14
54	Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER+) metastatic breast cancers (MBC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1040-1040	2.2	1
53	Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. <i>ESMO Open</i> , <b>2016</b> , 1, e000072	6	7
52	Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 6002-6009	12.9	12

51	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. <i>European Journal of Cancer</i> , <b>2016</b> , 56, 85-92	7.5	4
50	Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1086-1086	2.2	8
49	Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2516-2516	2.2	17
48	Outcomes of invasive ductal (ID) or invasive lobular (IL) early stage breast cancer in women treated with anastrozole or exemestane in the Canadian cancer trials Group MA.27.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 521-521	2.2	1
47	Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e14565-e14565	2.2	8
46	Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, LBA509-LBA509	2.2	2
45	Androgen receptor activation in HER2-negative breast cancer liver metastases.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11527-11527	2.2	
44	Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, LBA509-LBA509	2.2	
43	Phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin (E) in advanced solid tumors, with dose expansion in patients with GR-positive (GR+) triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e12550-e12550	2.2	
42	Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. <i>SpringerPlus</i> , <b>2016</b> , 5, 1033		5
41	Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases. <i>Cancer and Metastasis Reviews</i> , <b>2016</b> , 35, 323-32	9.6	9
40	Highlights of the 2015 San Antonio Breast Cancer Symposium. <i>Genes and Diseases</i> , <b>2016</b> , 3, 110-113	6.6	
39	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1738-1748	59.2	975
38	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2015</b> , 16, 575	2.8	20
37	Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. <i>Cancer Medicine</i> , <b>2015</b> , 4, 1289-93	4.8	6
36	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 56	8.3	21
35	Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4305-11	12.9	39
34	Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 1556-1568	21.7	63

33	Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3840-7	2.2	212
32	A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS1144-TPS1144	2.2	1
31	tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS1146-TPS1146	2.2	2
30	Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase 2, single-arm, multicenter study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 139-139	2.2	1
29	Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from two phase II, multicenter, single-arm studies.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 629-629	2.2	
28	Functional comparison between genomic subtypes and protein signal transduction networks in metastatic triple-negative breast cancer tumor and stroma to identify actionable therapeutic strategies.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e22155-e22155	2.2	
27	Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 635-635	2.2	1
26	Estrogen receptor-positive (ER+) metastatic breast cancer (MBC) patients (pts) with extreme responses (ERs) to capecitabine having tumors with genomic alterations in DNA repair and chromatin remodeling genes.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 555-555	2.2	
25	Scalp cooling alopecia prevention trial (SCALP).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS9660-TPS9660	2.2	
24	Evidence of PIK3CA and TP53 co-mutation in breast cancer identification on next-generation sequencing (NGS) of ERBB2 (HER2)-amplified residual disease following preoperative anti-HER2 therapy.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 625-625	2.2	
23	Genomic and protein alterations in 126 triple-negative (TN) metaplastic breast cancers.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1029-1029	2.2	
22	Secondary nonbreast malignancies (SNBM) after primary breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 112-112	2.2	
21	Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from 2 phase 2, multicenter, single-arm studies.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 140-140	2.2	
20	Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. <i>Lancet Oncology</i> , <b>2013</b> , 14, 1121-1128	2.7	93
19	Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 138, 829-37	4.4	32
18	A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 139, 107-13	4.4	49
17	Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 162ra154	17.5	463
16	Tesetaxel: Activity of an oral taxane as first-line treatment in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1016-1016	2.2	3



15	Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1017-1017	2.2	3
14	Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1018-1018	2.2	2
13	Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 547-547	2.2	
12	Phase III open-label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients (pts) with locally recurrent or metastatic breast cancer (MBC) previously treated with an anthracycline, a taxane, and capecitabine (ATC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS1140-TPS1140	2.2	
11	Iniparib plus chemotherapy in metastatic triple-negative breast cancer. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 205-14	59.2	671
10	Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 264-72	9.7	175
9	Developments in the systemic therapy of early-stage breast cancer. <i>European Journal of Cancer, Supplement</i> , <b>2007</b> , 5, 3-10	1.6	2
8	Gemcitabine and trastuzumab in metastatic breast cancer. <i>Seminars in Oncology</i> , <b>2003</b> , 30, 22-6	5.5	44
7	Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience. <i>Oncology</i> , <b>2003</b> , 17, 15-21	1.8	8
6	Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2812-23 <sup>2</sup>	2.2	928
5	Treatment for anthracycline-pretreated metastatic breast cancer. <i>Oncologist</i> , <b>2002</b> , 7 Suppl 6, 4-12	5.7	45
4	Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. <i>Clinical Breast Cancer</i> , <b>2002</b> , 3 Suppl 1, 17-20	3	43
3	Fulvestrant: clinical application of an estrogen receptor downregulator. <i>Clinical Therapeutics</i> , <b>2002</b> , 24 Suppl A, A31-40	3.5	1
2	Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. <i>Oncology</i> , <b>2002</b> , 16, 17-22	1.8	26
1	High dose chemotherapy for breast cancer: taking stock. <i>Oncologist</i> , <b>2000</b> , 5, 14-7	5.7	3